Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 May 7;13:143. doi: 10.1186/s12967-015-0494-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Conforti et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Biological characterization of HD- and Cys-MSCs. A: Morphology of bone marrow (BM)-derived mesenchymal stromal cells (MSCs) isolated from the cystinotic patient (Cys-MSCs, on the left) and from one representative healthy donor (HD-MSCs, on the right) at passage 2. Magnification x10. Cys-MSCs display the typical spindle-shape morphology of HD-MSCs. B: Calculated population doublings (PDs) from P1 to P5 of HD-MSCs (mean of 3 different HDs) and Cys-MSCs. Cys-MSCs show a lower proliferative capacity, as compared with HD-MSCs. C: ß-Galactosidase staining of MSCs isolated from the cystinotic patient (Cys-MSCs on the left) and from one representative healthy donor (HD-MSCs on the right). Senescence of the cells is indicated by the positivity for the staining. D: After cysteamine treatment, the percentage of Cys-MSCs late apoptotic cells becomes significantly higher than HD-MSCs’ one.*Indicates a p value lower than 0.05.